IgGenix Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $40M

  • Investors
  • 11

IgGenix General Information

Description

Developer of an antibody-based therapeutic platform intended to speed up the clinical response time against allergies. The company's platform engineers antibodies to capture allergens and endow them with powerful immune-modulating activities derived from the immunoglobulin G (IgG) antibody class, enabling the medical industry to combat life-threatening allergic reactions and cascades.

Contact Information

Website
www.iggenix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 681 Gateway Boulevard
  • Floor 4
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 681 Gateway Boulevard
  • Floor 4
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IgGenix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 02-Feb-2023 $40M Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A1) 26-Jul-2021 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 04-Aug-2020 $10M $10M Completed Clinical Trials - Phase 1
To view IgGenix’s complete valuation and funding history, request access »

IgGenix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A1
Series A 4,000,000 $0.000010 $0.1 $1.25 $1.25 1x $1.25 11.52%
To view IgGenix’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

IgGenix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an antibody-based therapeutic platform intended to speed up the clinical response time against allergies. T
Drug Discovery
South San Francisco, CA
8 As of 2026

Rockville, MD
 

Berkeley, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IgGenix Competitors (33)

One of IgGenix’s 33 competitors is Immunomic Therapeutics, a Venture Capital-Backed company based in Rockville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immunomic Therapeutics Venture Capital-Backed Rockville, MD
Actym Therapeutics Venture Capital-Backed Berkeley, CA
Adimab Venture Capital-Backed Lebanon, NH
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Byondis Corporation Nijmegen, Netherlands
You’re viewing 5 of 33 competitors. Get the full list »

IgGenix Patents

IgGenix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023375308-A1 Compositions and methods for treating and suppressing allergic responses Pending 09-Nov-2022
EP-4615503-A2 Compositions and methods for treating and suppressing allergic responses Pending 09-Nov-2022
EP-4615503-A4 Compositions and methods for treating and suppressing allergic responses Pending 09-Nov-2022
US-20250263472-A1 Compositions and methods for treating and suppressing allergic responses Pending 09-Nov-2022
WO-2024102700-A2 Compositions and methods for treating and suppressing allergic responses Inactive 09-Nov-2022 C07K16/16
To view IgGenix’s complete patent history, request access »

IgGenix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IgGenix Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
FemHealth Ventures Venture Capital Minority
Lilly USA Corporation Minority
Medical Incubator Japan Venture Capital Minority
SBI Investment Venture Capital Minority
Angel (individual) Minority
You’re viewing 5 of 11 investors. Get the full list »

IgGenix FAQs

  • When was IgGenix founded?

    IgGenix was founded in 2019.

  • Where is IgGenix headquartered?

    IgGenix is headquartered in South San Francisco, CA.

  • What is the size of IgGenix?

    IgGenix has 8 total employees.

  • What industry is IgGenix in?

    IgGenix’s primary industry is Drug Discovery.

  • Is IgGenix a private or public company?

    IgGenix is a Private company.

  • What is the current valuation of IgGenix?

    The current valuation of IgGenix is .

  • What is IgGenix’s current revenue?

    The current revenue for IgGenix is .

  • How much funding has IgGenix raised over time?

    IgGenix has raised $75M.

  • Who are IgGenix’s investors?

    FemHealth Ventures, Lilly USA, Medical Incubator Japan, SBI Investment, and are 5 of 11 investors who have invested in IgGenix.

  • Who are IgGenix’s competitors?

    Immunomic Therapeutics, Actym Therapeutics, Adimab, CytomX Therapeutics, and Byondis are some of the 33 competitors of IgGenix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process